Chemistry:Insulin icodec
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C280H435N71O87S6 |
| Molar mass | 6380.33 g·mol−1 |
Insulin icodec is an investigational ultralong-acting basal insulin analogue that is developed by Novo Nordisk.
It has a plasma half-life more than eight days[1] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.s[1]
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life.[2]
Insulin icodec is the international nonproprietary name.[3]
Research
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100.[4]
References
- ↑ 1.0 1.1 "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry 64 (13): 8942–8950. July 2021. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562.
- ↑ "Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing". BMJ Open Diabetes Research & Care 9 (1): e002301. August 2021. doi:10.1136/bmjdrc-2021-002301. PMID 34413118.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information 35 (1). 2021.
- ↑ "Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin". The New England Journal of Medicine 389 (4): 297–308. July 2023. doi:10.1056/NEJMoa2303208. PMID 37356066.
 |  |
